Isolation of tumor‐specific antibodies from effusions of ovarian carcinomas

Dorsett, Brent H.; Ioachim, Harry L.; Stolbach, Leo L.; Walker, John R.; Barber, Hugh R. K.

doi:10.1002/ijc.2910160510

Cited by 38 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most lung carcinomas are accompanied by a strong local cellular reaction that correlated in its amount, composition and distribution with the histologic type, grade and stage of the tumor (Ioachim et al, 1976). We have postulated that both tumor antigens and antibodies are present in greater amounts at the site of tumors (Dorsett et al, 1975;Ioachim 1976;Ioachim et al, 1976;Ioachim and Paluch, 1978) and based on this assumption we have successfully isolated tumor-reactive antibodies from eluates of lung carcinomas and from their effusions (Ioachirn et a!., 1976;Ioachim and Paluch, 1978. ) Undcr normal conditions, bronchial secretions contain substantial amounts of immunoglohulins, predominantly IgA, as part of the local immunologic barrier system of the lung (Gotz, 1974;Scrobogna et al, 1976).…”

mentioning

confidence: 99%

Reactive antibodies in the bronchial washings of lung cancer patients

Paluch

Ioachim

1979

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Lung-carcinoma-reactive antibodies have been previously isolated from tumor tissues and pleural effusions. To explore the immunoglobulin (Ig) content of bronchial secretions, bronchial washings of patients with inflammatory and neoplastic lung diseases were studied with respect to Ig levels and specificity. Expressed as Ig/potassium ratios, statistically significant increases in Ig levels were found in inflammatory diseases and even higher increases in lung carcinomas. The isolation of Ig from bronchial washings was achieved by dissociation of immune complexes at low pH, neutralization and subsequent purification by anion exchange chromatography. The isolated immunoglobulins were tested in indirect immunofluorescence against lung cancer cells of various histologic types in tissue cultures and fresh suspensions. Positive cytoplasmic fluorescence was obtained with cells of adeno carcinomas and squamous-cell carcinomas of the lung but not with cells of normal lung. The accessibility of bronchial washings makes the investigation of their lung-cancer-reactive immunoglobulins relatively easy and raises the possibility of its eventual conversion into a screening test.

show abstract

mentioning

confidence: 99%

Reactive antibodies in the bronchial washings of lung cancer patients

Paluch

Ioachim

1979

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…This fluid is similar in composition to serum and is in immediate contact with the tumour. Dorsett et al (1975) show that this fluid contains tumourassociated immunoglobulin. In the present study, IgG was isolated from ascitic fluids in an attempt to detect tumour antigen in the patient's serum.…”

mentioning

confidence: 87%

Isolation of tumour-associated immunoglobulins from ascitic fluid

Hill¹,

Daunter²,

Khoo³

et al. 1978

Br J Cancer

View full text Add to dashboard Cite

“…Immunoglobulins which were liberated from ascitic ICs by dissociating reagents were shown to react with ovarian cancer tissues by immunohistological staining [9][10][11][12]15]. We also attempted to purify individual constituents from ascitic ICs in a similar way, but found that this approach had several inherent technical limitations for further evaluation, including only partial dissociation with accompanying denaturation and low titers of the resulting heterogeneous antibodies.…”

Section: Discussionmentioning

confidence: 99%

“…The availability of large amounts of ICs from ascites, compared with those from the patient's serum, has facilitated their characterization [7][8][9][10][11][12][13][14][15]. Although individual nonantigenic constituents bound within the ascitic ICs have been characterized, the origin and nature of antigenic components remain to be identified, mainly due to technical problems and the lack of suitable probes [16].…”

Section: Introductionmentioning

confidence: 99%

Detection of Epithelial Ovarian-Cancer-Associated Antigens Involved in Immune Complexes by Monoclonal Antibodies

Kawata

Sekiya²

1998

Tumor Biol

View full text Add to dashboard Cite

To detect antigenic molecules involved in immune complexes (ICs) in patients with epithelial ovarian cancer, we developed several monoclonal antibodies (Mabs) by hybridoma technology from mice immunized with ovarian cancer tissues. Hybridoma supernatants were differentially screened with a panel of ICs purified from ascites of patients with ovarian cancer and with ICs from pooled normal human sera by the enzyme-linked immunosorbent assay (ELISA). From about 6,000 supernatants screened in 6 fusions, 4 Mabs showing preferential binding to the ascitic ICs were selected. Their antibody specificity was further examined with serum-free conditioned media of various cancer cell lines by an ELISA inhibition assay. The reactivity of 3 Mabs was inhibited by the media of epithelial ovarian cancer cell lines, but not by any of the nonovarian cell lines tested, suggesting that the target antigens were derived from ovarian cancer cells. Furthermore, ICs detected by one Mab, designated 2F11, were elevated in the sera from 18 of 42 (42.9%) patients with epithelial ovarian cancer, but not in those from 39 patients with benign ovarian tumors or from 29 healthy individuals (with the exception of 1 serum), using sandwich ELISA with protein A as the capture reagent.

show abstract

Isolation of tumor‐specific antibodies from effusions of ovarian carcinomas

Cited by 38 publications

References 13 publications

Reactive antibodies in the bronchial washings of lung cancer patients

Reactive antibodies in the bronchial washings of lung cancer patients

Isolation of tumour-associated immunoglobulins from ascitic fluid

Detection of Epithelial Ovarian-Cancer-Associated Antigens Involved in Immune Complexes by Monoclonal Antibodies

Contact Info

Product

Resources

About